Abstract:As the mutant estrogen receptor (ER) continues to be characterized, breast cancer is becoming increasingly difficult to cure when treated with hormone therapy. In this regard, a strategy to selectively and effectively degrade the ER might be an effective alternative to endocrine therapy for breast cancer. In a previous study, we identified a novel series of 7-oxabicyclo[2.2.1]heptene sulfonamide (OBHSA) compounds as full ER antagonists while lacking the prototypical ligand side chain that has been widely used to induce antagonism of ERα. Further crystal structure studies and phenotypic assays revealed that these compounds are selective estrogen receptor degraders (SERDs) with a new mechanism of action. However, from a drug discovery point of view, there still is room to improve the potency of these OBHSA compounds. In this study, we have developed new classes of SERDs that contain the OBHSA core structure and different side chains, e.g., basic side chains, long alkyl acid side chains, and glycerol ether side chains, to simply mimic the degrons of proteolysis targeting chimera (PROTAC) and then investigated the structure-activity relationships of these PROTAC-like hybrid compounds. These novel SERDs could effectively inhibit MCF-7 cell proliferation and demonstrated good ERα degradation efficacy. Among the SERDs, compounds 17d, 17e and 17g containing a basic side chain with a N-trifluoroethyl substituent and a para methoxyl group at the phenyl group of the sulfonamide turned out to be the best candidates for ER degraders. A further docking study of these compounds with ERα elucidates their structure-activity relationships, which provides guidance to design new PROTAC degrons targeting ER for breast cancer therapy. Lastly, easy modification of these PROTAC-like SERDs enables further fine-tuning of their pharmacokinetic properties, including oral availability.

Identification of New Small-Molecule Inducers of Estrogen-related Receptor Α (errα) Degradation

A New Class of 1,3,5-Triazine-based Selective Estrogen Receptor Degraders (serds): Lead Optimization, Molecular Docking and Dynamic Simulation.

Identification of Pyrido[1,2-α]pyrimidine-4-ones As New Molecules Improving the Transcriptional Functions of Estrogen-Related Receptor Α

Exploring the PROTAC Degron Candidates: OBHSA with Different Side Chains As Novel Selective Estrogen Receptor Degraders (Serds)

Discovery of ERD-3111 as a Potent and Orally Efficacious Estrogen Receptor PROTAC Degrader with Strong Antitumor Activity

Discovery of Novel 2H-Chromene-3-carbonyl Derivatives As Selective Estrogen Receptor Degraders (serds): Design, Synthesis and Biological Evaluation.

Identification and Structure-Activity Relationships of a Novel Series of Estrogen Receptor Ligands Based on 7-Thiabicyclo[2.2.1]hept-2-ene-7-oxide.

Identification of 10-Dehydrooxyglycyuralin E As a Selective Human Estrogen Receptor Alpha Partial Agonist.

Recent advance in the design of small molecular modulators of estrogen-related receptors.

Discovery of non-antiproliferative selective estrogen receptor degraders (SERDs) based on scaffold optimization of elacestrant

Discovery of New Estrogen-Related Receptor α Agonists via a Combination Strategy Based on Shape Screening and Ensemble Docking

Discovery of ERD-12310A As an Exceptionally Potent and Orally Efficacious PROTAC Degrader of Estrogen Receptor Α (Erα)

Design, Synthesis and Biological Evaluation of Novel Indone Derivatives As Selective ERβ Modulators

Discovery of Thiochroman Derivatives as Potent, Oral Selective Estrogen Receptor Degraders and Antagonists for the Treatment of Endocrine-Resistant Breast Cancer

1-Phenyl-4-benzoyl-1h-1,2,3-triazoles As Orally Bioavailable Transcriptional Function Suppressors of Estrogen-Related Receptor Α

Novel 11Β-Substituted Estradiol Conjugates: Transition from ERα Agonizts to Effective PROTAC Degraders

Benzothiophene Derivatives As Selective Estrogen Receptor Covalent Antagonists: Design, Synthesis and Anti-Erα Activities.

Discovery of Thieno[2,3-e]indazole Derivatives As Novel Oral Selective Estrogen Receptor Degraders with Highly Improved Antitumor Effect and Favorable Druggability

Design, Synthesis, and Biological Evaluation of Novel Phenol Ether Derivatives As Non-Covalent Proteasome Inhibitors.

X-ray Crystallography Study and Optimization of Novel Benzothiophene Analogs As Potent Selective Estrogen Receptor Covalent Antagonists (sercas) with Improved Potency and Safety Profiles.

Design, synthesis, biological evaluation and molecular docking studies of novel 3-aryl-4-anilino-2H-chromen-2-one derivatives targeting ERα as anti-breast cancer agents